Cancer in Vitro Diagnostics (IVD) Market Report 2025

The cancer in vitro diagnostics (IVD) market size has grown strongly in recent years. It will grow from $13.36 billion in 2024 to $14.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising research in cancer biomarkers, increasing number of oncology clinical trials requiring diagnostic testing, expanding government health initiatives, growth in laboratory infrastructure, and increasing funding for biotechnology research.

The cancer in vitro diagnostics (IVD) market size is expected to see strong growth in the next few years. It will grow to $18.62 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to government and NGO-led cancer screening initiatives, an aging population, increasing awareness of early cancer detection, expanded reimbursement coverage, and growing adoption of point-of-care (POC) diagnostics. Major trends during this period include the expansion of liquid biopsy technologies, advancements in next-generation sequencing, integration of artificial intelligence and machine learning, incorporation of microfluidics, and adoption of digital pathology solutions.

The increasing incidence of cancer is expected to propel the growth of the cancer in vitro diagnostics (IVD) market going forward. Cancer refers to the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and form tumors. The rising incidence of cancer is largely driven by the aging population, as longer life expectancy and reduced mortality from infectious diseases result in more elderly individuals, who are at higher risk of developing cancer. Cancer in vitro diagnostics (IVD) support early detection, monitoring, and management of the disease through laboratory tests on patient samples, enabling timely treatment decisions and improved outcomes. For instance, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that new cancer cases globally reached 20 million in 2022 and are projected to rise to 35 million by 2050, representing a 77% increase. Therefore, the rising incidence of cancer is driving the growth of the cancer in vitro diagnostics (IVD) market.

Key companies in the cancer in vitro diagnostics (IVD) market are focusing on technological advancements, such as CE-marked IVD cancer testing kits, to improve accessibility, accuracy, and standardization of hereditary cancer testing across clinical settings. CE-marked IVD cancer testing kits are diagnostic assays compliant with the European Union's in vitro diagnostic directive (IVDD), ensuring validated performance, safety, and quality for laboratory use. For instance, in February 2022, Invitae, a US-based medical genetics company, launched FusionPlex Dx and LiquidPlex Dx in Europe. FusionPlex Dx provides sensitive detection of low-frequency variants in FFPE samples, while LiquidPlex Dx enables non-invasive cancer genomic profiling from blood, facilitating personalized treatment and disease monitoring when tissue samples are limited.

In February 2022, BD (Becton, Dickinson and Company), a US-based medical technology firm, acquired Cytognos from Vitro S.A., a Spain-based biotechnology company specializing in cancer IVD. This acquisition allows BD to expand its portfolio from cancer discovery and diagnosis into post-treatment monitoring, supporting the full spectrum of patient care.

Major players in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., and Tulip Diagnostics (P) Ltd.

North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer in vitro diagnostics (IVD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer in vitro diagnostics (IVD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Cancer in vitro diagnostics (IVD) refers to diagnostic tests conducted outside the human body on samples like blood, tissue, or other bodily fluids to detect, monitor, or manage cancer. These tests aid in early detection, diagnosis, prognosis, and treatment selection by analyzing biomarkers, genetic mutations, and other cancer-related indicators.

The primary product types of cancer in vitro diagnostics (IVD) include reagents and kits, instruments, and software and services. Reagents and kits are ready-to-use chemicals and prepared testing materials designed to detect cancer markers and analyze samples in IVD tests. They employ technologies such as clinical chemistry, immunochemistry or immunoassays, hematology, coagulation and hemostasis, microbiology, molecular diagnostics, and others. These diagnostics cover various cancer types, including breast, lung, prostate, and colorectal cancers, and serve end users such as hospitals, laboratories, academic institutions, point-of-care testing centers, and patient self-testing programs.

The cancer in vitro diagnostics (IVD) market research report is one of a series of new reports that provides cancer in vitro diagnostics (IVD) market statistics, including cancer in vitro diagnostics (IVD) industry global market size, regional shares, competitors with a cancer in vitro diagnostics (IVD) market share, cancer in vitro diagnostics (IVD) market segments, market trends and opportunities, and any further data you may need to thrive in the cancer in vitro diagnostics (IVD) industry. This cancer in vitro diagnostics (IVD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer in vitro diagnostics (IVD) market consists of revenues earned by entities by providing services such as cancer screening, early detection testing, diagnostic analysis, and personalized treatment guidance. The market value includes the value of related goods sold by the service provider or contained within the service offering. The cancer in vitro diagnostics (IVD) market also includes sales of reagents, assay kits, diagnostic instruments, molecular diagnostic platforms, and immunoassay systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.